Browsing by Author XIE ZHIGANG

Showing results 1 to 15 of 15
Issue DateTitleAuthor(s)
Sep-2008A new strategy to induce effective antitumour response in vitro and in vivoWang, M.; Xie, Z. ; Shi, M.; Lu, H.; Yu, M.; Hu, M.; Lu, F.; Ma, Y.; Shen, B.; Guo, N.
2008ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograftJasinghe, V.J. ; Xie, Z. ; Zhou, J. ; Khng, J.; Poon, L.-F. ; Senthilnathan, P. ; Chen, C.-S. ; Albert, D.H.; Davidsen, S.K.
2008Construction and functional identification of a novel trivalent anti-ErbB2/anti-CD16 bispecific antibodyLu, H.; Wang, M.; Shi, M.; Hu, M.; Yu, M.; Shen, B.; Guo, N.; Ma, Y.; Xie, Z. 
2011Determinants of sensitivity to DZNep induced Apoptosis in multiple myeloma cellsXie, Z. ; Bi, C.; Cheong, L.L.; Liu, S.C.; Huang, G. ; Zhou, J. ; Yu, Q.; Chen, C.-S.; Chng, W.J.
2009Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AMLZhou, J. ; Bi, C.; Janakakumara, J.V. ; Liu, S.-C.; Chng, W.-J.; Tay, K.-G. ; Poon, L.-F. ; Xie, Z. ; Palaniyandi, S. ; Chen, C.-S. ; Yu, H. ; Glaser, K.B.; Albert, D.H.; Davidsen, S.K.
2009Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AMLZhou, J. ; Bi, C.; Janakakumara, J.V. ; Liu, S.-C.; Chng, W.-J. ; Tay, K.-G. ; Poon, L.-F. ; Xie, Z. ; Palaniyandi, S. ; Chen, C.-S. ; Yu, H. ; Glaser, K.B.; Albert, D.H.; Davidsen, S.K.
2008In vitro and in vivo antitumor effect of a trivalent bispecific antibody targeting ErbB2 and CD16Lu, H.; Shi, M.; Wang, M.; Hu, M.; Yu, M.; Shen, B.; Guo, N.; Ma, Y.; Xie, Z. 
2008In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptorZhou, J. ; Khng, J.; Jasinghe, V.J.; Bi, C.; Poon, L.F.; Xie, Z. ; Chen, C.-S. ; Neo, C.H.S.; Pan, M.; Yu, H. ; Yeoh, A.E.-J.; Lu, Y. ; Glaser, K.B.; Albert, D.H.; Davidsen, S.K.
2008In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptorZhou, J. ; Khng, J.; Jasinghe, V.J. ; Bi, C.; Poon, L.F. ; Xie, Z. ; Chen, C.-S. ; Neo, C.H.S.; Pan, M.; Yu, H. ; Yeoh, A.E.-J.; Lu, Y. ; Glaser, K.B.; Albert, D.H.; Davidsen, S.K.
2008In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptorZhou, J. ; Khng, J.; Jasinghe, V.J. ; Bi, C.; Poon, L.F. ; Xie, Z. ; Chen, C.-S. ; Neo, C.H.S.; Pan, M.; Yu, H. ; Yeoh, A.E.-J. ; Lu, Y. ; Glaser, K.B.; Albert, D.H.; Davidsen, S.K.
2008Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasionXie, Z. ; Choong, P.F. ; Poon, L.F. ; Zhou, J. ; Khng, J. ; Jasinghe, V.J. ; Palaniyandi, S. ; Chen, C.-S. 
2013Plasma membrane proteomics identifies biomarkers associated with MMSET overexpression in t(4;14) multiple myelomaXie, Z. ; Gunaratne, J.; Cheong, L.L.; Liu, S.C.; Koh, T.L.; Huang, S.; Blackstock, W.P.; Chng, W.J.
2007Synergistic antileukemia effect of genistein and chemotherapy in mouse xenograft model and potential mechanism through MAPK signalingShen, J.; Tai, Y.-C. ; Zhou, J. ; Stephen, Wong C.-H. ; Xie, Z. ; Chen, C.-S. ; Cheang, P.T.S. ; Han, J.-H. ; Fred, Wong W.-S. ; Khan, M. 
Jan-2008Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathwayZhou, J. ; Pan, M.; Xie, Z. ; Loh, S.-L.; Bi, C.; Tai, Y.-C.; Lilly, M.; Lim, Y.-P. ; Han, J.-H.; Glaser, K.B.; Albert, D.H.; Davidsen, S.K.; Chen, C.-S.
Feb-2011Therapeutic potential of antisense oligodeoxynucleotides in downregulating p53 oncogenic mutations in cancersXie, Z. ; Chng, W.J.; Tay, K.G. ; Liu, S.C.; Zhou, J. ; Chen, C.-S.